Novavax Inc. ($NVAX) Stock Forecast: Down 5.0% Today

What is Novavax Inc.?

Novavax (NVAX) is a biotechnology company focused on developing vaccines for infectious diseases.

Why is Novavax Inc. going down?

NVAX stock is down 5.0% on Aug 1, 2025 15:26

• The broader market experienced mixed trading today.
• Novavax closed at $6.85, showing a -2.28% shift from the previous trading day.
• Possibly disappointing news related to the company's vaccine development progress or financial performance.
• General market sentiment impacting biotech stocks negatively.
• Investors reacting to potential delays in regulatory approvals or clinical trial results.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax ( NVAX ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.

https://www.zacks.com/stock/news/2640592/novavax-nvax-sees-a-more-significant-dip-than-broader-market-some-facts-to-know

Trending Today

Cardano ($ADA) Crypto Forecast: Down 5.0% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.2% Today

XRP ($XRP) Crypto Forecast: Down 5.1% Today

Chainlink ($LINK) Crypto Forecast: Down 5.4% Today

Lithia Motors Inc. ($LAD) Stock Forecast: Up 5.1% Today

ONEOK Inc. ($OKE) Stock Forecast: Down 5.0% Today

Transdigm Group Incorporated Inc. ($TDG) Stock Forecast: Down 12.7% Today

Eaton Corporation PLC ($ETN) Stock Forecast: Down 6.7% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 7.2% Today

Pfizer Inc. ($PFE) Stock Forecast: Up 5.0% Today

Novavax Inc. Price History

08.04.2025 - NVAX Stock was up 13.9%

• Novavax (NVAX) saw a substantial bullish upturn after exceeding earnings and revenue expectations by a significant margin in the first quarter.
• The market responded favorably to Novavax's exceptional quarterly earnings and revenue beat, indicating investor trust in the company's progress and future prospects.
• The upbeat financial outcomes and potential pipeline advancements announced during the earnings call likely contributed to the positive momentum in NVAX stock.
• In conclusion, Novavax's strong performance and optimistic market sentiment steered the stock towards a bullish path, underscoring the company's resilience and growth potential within the biotechnology industry.

19.04.2025 - NVAX Stock was down 5.6%

• The company received limited approval from the FDA for its COVID-19 vaccine, Nuvaxovid, with restrictions on usage for specific age groups and high-risk individuals.
• Despite securing FDA approval, the stock faced a bearish trend, possibly due to concerns about the limited target population for the vaccine.
• The milestone payment of $175 million from partner Sanofi SA did not seem to have a positive impact on the stock's performance.
• The market may be reacting to the news of FDA approval with new conditions, leading to uncertainty about the vaccine's widespread adoption and revenue potential.

19.04.2025 - NVAX Stock was down 6.7%

• Novavax's stock experienced a bearish movement despite the FDA granting limited approval for its COVID-19 vaccine.
• The restricted use of the vaccine to specific age groups and high-risk individuals might have raised concerns about the company's market potential and revenue prospects.
• Investors may be disappointed by the limited scope of the FDA approval, leading to a sell-off of NVAX shares as they reassess the company's position in the competitive vaccine market.
• The market reaction suggests that investors were expecting broader approval for Novavax's vaccine, and the current restrictions could impact the company's ability to capture a larger market share and generate significant revenue.

01.07.2025 - NVAX Stock was down 5.0%

• The broader market experienced mixed trading today.
• Novavax closed at $6.85, showing a -2.28% shift from the previous trading day.
• Possibly disappointing news related to the company's vaccine development progress or financial performance.
• General market sentiment impacting biotech stocks negatively.
• Investors reacting to potential delays in regulatory approvals or clinical trial results.

09.04.2025 - NVAX Stock was down 12.2%

• Novavax (NVAX) reported impressive first-quarter earnings and revenue beats, with a significant increase in revenues recognized from the termination of advanced purchase agreements.
• Despite the positive financial results, the market may have reacted bearishly due to profit-taking after a recent rally in the stock price.
• Investors might be uncertain about the stock's future performance, considering the focus on pipeline updates during the earnings call and the overall market sentiment.

25.06.2025 - NVAX Stock was down 8.5%

• Despite Novavax (NVAX) sharing promising results for their bird flu vaccine in primates, the stock experienced a bearish movement.
• The market might have reacted negatively due to profit-taking by investors after a recent uptrend in the stock price.
• Investors could be cautious about the company's ability to translate positive vaccine results into commercial success in the competitive pharmaceutical industry.
• The bearish movement could also be influenced by broader market factors or sector rotation, leading to a sell-off in biotech stocks despite positive news from Novavax.

02.06.2025 - NVAX Stock was up 5.4%

• NVAX stock experienced a bearish movement, decreasing by -2.15%.
• The positive market sentiment did not reflect on NVAX, suggesting company-specific factors influenced the stock's decline.
• Investors might be reacting to recent news or developments within NVAX, leading to the downward movement despite the overall bullish market trend.
• Traders should keep an eye on upcoming announcements or updates from NVAX to better understand the stock's performance in the near future.

21.04.2025 - NVAX Stock was down 5.5%

• Novavax's stock saw a decline despite obtaining FDA approval for its COVID-19 vaccine, Nuvaxovid, which received limited approval specifically for high-risk groups and seniors.
• The FDA's decision to restrict annual COVID-19 booster approvals to high-risk individuals and request further trials for healthy adults may have influenced investor sentiment negatively towards Novavax's stock.
• The market's response could be linked to the stricter clinical trial standards set by the FDA, potentially causing concerns about Novavax's upcoming vaccine projects and commercialization prospects.
• Despite achieving a regulatory milestone and receiving a milestone payment from partner Sanofi SA, the market's emphasis on limited approval and safety evaluations likely contributed to the bearish movement in NVAX stock.

17.05.2025 - NVAX Stock was down 5.1%

• Despite promising results indicating a robust immune response in seniors from Novavax's COVID-flu combo shot, the stock trended bearishly.
• Investor profit-taking, following a recent uptick in the stock price, may have contributed to the negative market reaction.
• Concerns about Novavax's capability to effectively launch and compete with other vaccine producers in the market might have influenced investor sentiment.
• The stock's decline could also reflect broader market trends or sector rotations affecting biotechnology companies.

28.04.2025 - NVAX Stock was down 5.1%

• The decline in NVAX stock could be attributed to heightened competition and uncertainty in the vaccine sector.
• Moderna's submission to the FDA for an enhanced COVID-19 vaccine tailored to a prevalent variant might have sparked concerns about Novavax's market position and competitiveness.
• Additionally, the retraction of Moderna's FDA submission for a COVID-flu combination vaccine could have contributed to the pessimism surrounding vaccine stocks, including NVAX.
• In general, the updates and setbacks in the vaccine field related to Moderna may have eclipsed Novavax's performance, resulting in a negative shift in NVAX stock.

08.06.2025 - NVAX Stock was up 5.6%

• Factors contributing to the bullish movement in NVAX stock include:
• Despite a slight decline in the broader market, NVAX demonstrated resilience by closing higher, showcasing strong investor confidence.
• The potential influence of RFK Jr. in the vaccine approval process may have had a positive impact on NVAX, with the company being mentioned alongside other vaccine manufacturers such as Moderna and Pfizer.
• FDA chief Prasad's decision to restrict COVID-19 vaccine approval to specific groups could have positioned NVAX favorably, potentially increasing demand for its vaccine candidates.
• Growing macro risks like tariffs and inflation may have driven investors to seek safety in healthcare stocks like NVAX, leading to an increase in its price.

24.05.2025 - NVAX Stock was up 5.1%

• NVAX displayed a notable upward trend, ending at $6.41 with a +1.75% rise compared to the previous day.
• This positive momentum in NVAX could be linked to advancements in vaccine development or favorable updates on their clinical trials.
• Despite the market's decline, NVAX's performance reflects investor confidence in its future potential.
• Investors seem hopeful about NVAX's capacity to tackle global health issues, contributing to the stock's upward trajectory.